+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination



The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination



Vaccine 26(35): 4513-4518



We estimated the health and economic benefits of preventing recurrent respiratory papillomatosis (RRP) through quadrivalent human papillomavirus (HPV) vaccination. We applied a simple mathematical model to estimate the averted costs and quality-adjusted life years (QALYs) saved by preventing RRP in children whose mothers had been vaccinated at age 12 years. Under base case assumptions, the prevention of RRP would avert an estimated USD 31 (range: USD 2-178) in medical costs (2006 US dollars) and save 0.00016 QALYs (range: 0.00001-0.00152) per 12-year-old girl vaccinated. Including the benefits of RRP reduced the estimated cost per QALY gained by HPV vaccination by roughly 14-21% in the base case and by <2% to >100% in the sensitivity analyses. More precise estimates of the incidence of RRP are needed, however, to quantify this impact more reliably.

(PDF emailed within 0-6 h: $19.90)

Accession: 056437441

Download citation: RISBibTeXText

PMID: 18598734

DOI: 10.1016/j.vaccine.2008.06.045


Related references

Juvenile-Onset Recurrent Respiratory Papillomatosis: The Benefits of Quadrivalent Human Papillomavirus Vaccination Continue to Accrue. Journal of Infectious Diseases 217(2): 177-178, 2017

Treatment With Quadrivalent Human Papillomavirus Vaccine for Juvenile-Onset Recurrent Respiratory Papillomatosis: Case Report and Review of the Literature. Journal of the Pediatric Infectious Diseases Society 6(4): 380-385, 2017

Intersurgical interval increased with use of quadrivalent human papillomavirus vaccine (Gardasil) in a pediatric patient with recurrent respiratory papillomatosis: A case report. International Journal of Pediatric Otorhinolaryngology 91: 166-169, 2017

Multi-Year Effect of Human Papillomavirus Vaccination on Recurrent Respiratory Papillomatosis. Laryngoscope 2019, 2019

Economic, Public Health, and Humanistic Impact of a Quadrivalent Human Papillomavirus (Hpv6/11/16/18) Vaccination Program for Females Age 9-11 Years in Mexico. Value in Health 18(7): A871, 2015

Reductions in human papillomavirus-disease resource use and costs with quadrivalent human papillomavirus (types 6, 11, 16, and 18) recombinant vaccination: the FUTURE Study Economic Evaluation. Value in Health 11(7): 1022-1032, 2008

Economic, Public Health, And Humanistic Impact of a Quadrivalent Human Papillomavirus (Hpv6/11/16/18) Vaccination Program For Females And Males Age 9-11 Years in Mexico. Value in Health 18(7): A821-A822, 2015

Polymorphism of transporter associated with antigen presentation 1 as a potential determinant for severity of disease in recurrent respiratory papillomatosis caused by human papillomavirus types 6 and 11. Journal of Infectious Diseases 189(5): 871-879, 2004

Cost of Preventing, Managing, and Treating Human Papillomavirus (HPV)-Related Diseases in Sweden before the Introduction of Quadrivalent HPV Vaccination. Plos One 10(9): E0139062-E0139062, 2016

Clinical course of recurrent respiratory papillomatosis: comparison between aggressiveness of human papillomavirus-6 and human papillomavirus-11. Head and Neck 37(11): 1625-1632, 2016

Human papillomavirus-11-associated recurrent respiratory papillomatosis is more aggressive than human papillomavirus-6-associated disease. Pediatric and Developmental Pathology 4(1): 68-72, 2001

Recurrent laryngeal papillomatosis with oesophageal involvement in a 2 year old boy: successful treatment with the quadrivalent human papillomatosis vaccine. International Journal of Pediatric Otorhinolaryngology 79(2): 262-266, 2015

Recurrent laryngeal papillomatosis: successful treatment with human papillomavirus vaccination. Archives of Disease in Childhood 96(5): 476-477, 2011

Detection of human papillomavirus in the upper respiratory tract in children without recurrent respiratory papillomatosis. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 47(12): 974-977, 2014

Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study. Clinical Infectious Diseases 54(7): 891-898, 2012